← Browse by Condition
Medical Condition

chronic myeloid leukemia cml

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT06514534 Phase 2
Recruiting

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Enrollment
20 pts
Location
France
Sponsor
Novartis Pharmaceuticals
View Trial →